Inhibikase Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Inhibikase Therapeutics using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Sep 2024 | 2024-11-14 | $-0.65 | $-0.67 | 2.99 % |
Jun 2024 | 2024-08-14 | $-0.66 | $-0.67 | 1.49 % |
Mar 2024 | 2024-05-15 | $-0.73 | $-0.79 | 7.59 % |
Dec 2023 | 2024-03-27 | $-0.64 | $-0.85 | 24.7 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Sep 2022 | 2022-11-14 | $7.29K | $200.00K | -96.4 % |
Jun 2022 | 2022-08-12 | $6.55K | $300.00K | -97.8 % |
Mar 2022 | 2022-05-16 | $46.03K | $300.00K | -84.7 % |
Dec 2021 | 2022-03-31 | $1.94M | $300.00K | 548.0 % |
Inhibikase Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3.
Inhibikase Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was $-0.65, which beat the estimate of $-0.67.
Inhibikase Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was {{actualEPS}}, which hit the estimate of {{estEPS}}.
Browse earnings estimates, EPS, and revenue on all stocks.